Fig. 3
FGF19ΔKLB improved hepatic functions and inflammation in Mdr2-/- mice. (A) Schematic diagram of experimental design. Four-week-old Mdr2-/- mice were treated by daily i.p. injections of PBS, FGF19WT or FGF19 ΔKLB (n = 5 per group) for eight weeks. (B-D) Serum alanine transaminase (ALT) (B), aspartate transaminase (AST) (C), alkaline phosphatase (ALP) (D) levels were determined after chronic treatment. (E-F) Serum levels of TNFα and IL-6 were measured by ELISA. (G) Representative H&E staining of liver tissues in Mdr2−/− mice treated by PBS, FGF19WT or FGF19ΔKLB. (H-I) Hepatic pro-inflammatory cytokines including Il6 (H) and TNF-α (I) mRNA levels. (J-K) Immunofluorescence (J) and semi-quantification (K) of F4/80 positive cells in liver tissues. Mean ± SEM was chosen to represent the data; **p < 0.01, ***p < 0.001, ****p < 0.0001; (B-D, F, G, I) conventional one-way ANOVA, then Tukey